KEGG   DISEASE: 乳癌
エントリ  
H00031                                                             

名称    
乳癌
概要    
Breast cancer is the leading cause of cancer death among women worldwide. The vast majority of breast cancers are carcinomas that originate from cells lining the milk-forming ducts of the mammary gland. The molecular subtypes of breast cancer, which are based on the presence or absence of hormone receptors (estrogen and progesterone subtypes) and human epidermal growth factor receptor-2 (HER2), include: hormone receptor positive and HER2 negative (luminal A subtype), hormone receptor positive and HER2 positive (luminal B subtype), hormone receptor negative and HER2 positive (HER2 positive), and hormone receptor negative and HER2 negative (basal-like or triple-negative breast cancers (TNBCs)). Hormone receptor positive breast cancers are largely driven by the estrogen/ER pathway. In HER2 positive breast tumours, HER2 activates the PI3K/AKT and the RAS/RAF/MAPK pathways, and stimulate cell growth, survival and differentiation. In patients suffering from TNBC, the deregulation of various signalling pathways (Notch and Wnt/beta-catenin), EGFR protein have been confirmed. In the case of breast cancer only 8% of all cancers are hereditary, a phenomenon linked to genetic changes in BRCA1 or BRCA2. Somatic mutations in only three genes (TP53, PIK3CA and GATA3) occurred at >10% incidence across all breast cancers.
カテゴリ  
がん
階層分類  
ヒト疾患 [BR:jp08402]
 がん
  乳房および女性生殖器のがん
   H00031  乳癌
ICD-11 による疾患分類 [BR:jp08403]
 02 Neoplasms
  Malignant neoplasms, except of lymphoid, haematopoietic, central nervous system or related tissues
   Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues
    Malignant neoplasms of breast
     2C61  Invasive carcinoma of breast
      H00031  乳癌
パスウェイ 
hsa05224  乳癌
関連パスウェイ
hsa05200  Pathways in cancer
hsa05206  MicroRNAs in cancer
hsa05205  Proteoglycans in cancer
ネットワーク
nt06270  Breast cancer
  エレメント
N00020  Amplified FGFR to RAS-ERK signaling pathway
N00022  ERBB2-overexpression to RAS-ERK signaling pathway
N00034  ERBB2-overexpression to PI3K signaling pathway
N00038  Amplified FGFR to PI3K signaling pathway
N00041  EGFR-overexpression to RAS-ERK signaling pathway
N00042  EGFR-overexpression to PI3K signaling pathway
N00049  Mutation-activated PI3K to PI3K signaling pathway
N00050  Amplified PI3K to PI3K signaling pathway
N00052  Mutation-inactivated PTEN to PI3K signaling pathway
N00059  FZD7-overexpression to Wnt signaling pathway
N00060  LRP6-overexpression to Wnt signaling pathway
N00087  NOTCH-overexpression to Notch signaling pathway
N00115  Mutation-inactivated TP53 to transcription
N00275  Amplified CCND1 to cell cycle G1/S
N00287  ESR1-positive to nuclear-initiated estrogen signaling pathway
病因遺伝子 
ESR1 (positive) [HSA:2099] [KO:K08550]
FGFR1 (amplification) [HSA:2260] [KO:K04362]
PIK3CA (mutation) [HSA:5290] [KO:K00922]
PTEN (mutation) [HSA:5728] [KO:K01110]
p53 (mutation) [HSA:7157] [KO:K04451]
CCND1 (amplification) [HSA:595] [KO:K04503]
ERBB2 (overexpression) [HSA:2064] [KO:K05083]
EGFR (overexpression) [HSA:1956] [KO:K04361]
KIT (overexpression) [HSA:3815] [KO:K05091]
Notch1 (overexpression) [HSA:4851] [KO:K02599]
Notch4 (overexpression) [HSA:4855] [KO:K20996]
FZD7 (overexpression) [HSA:8324] [KO:K02432]
LRP6 (overexpression) [HSA:4040] [KO:K03068]
BRCA1 (germline mutation, hypermethylation) [HSA:672] [KO:K10605]
BRCA2 (germline mutation) [HSA:675] [KO:K08775]
発癌物質  
Estrogen-progestogen menopausal therapy (combined)
Estrogen-progestogen oral contraceptives (combined)
Estrogen therapy, postmenopausal
Oral contraceptives, sequential
Radium-224 and its decay products
X- and gamma-radiation
治療薬   
デキサメタゾン [DR:D00292]
デキサメタゾンリン酸エステルナトリウム [DR:D00975]
ベタメタゾンリン酸エステルナトリウム [DR:D00972]
トリアムシノロンアセトニド [DR:D00983]
ヒドロコルチゾン [DR:D00088]
ヒドロコルチゾンコハク酸エステルナトリウム [DR:D00978]
ベタメタゾン [DR:D00244]
プレドニゾロン [DR:D00472]
プレドニゾロンコハク酸エステルナトリウム [DR:D01239]
メチルプレドニゾロン [DR:D00407]
エチニルエストラジオール [DR:D00554]
メドロキシプロゲステロン酢酸エステル [DR:D00951]
リュープロレリン酢酸塩 [DR:D00989]
ゴセレリン酢酸塩 [DR:D00573]
メピチオスタン [DR:D01602]
メトトレキサート [DR:D00142]
エベロリムス [DR:D02714]
シクロホスファミド水和物 [DR:D00287]
フルオロウラシル [DR:D00584]
テガフール [DR:D01244]
カペシタビン [DR:D01223]
ドキシフルリジン [DR:D01309]
シタラビン [DR:D00168]
ゲムシタビン塩酸塩 [DR:D01155]
テガフール・ウラシル [DR:D02131]
テガフール・ギメラシル・オテラシルカリウム [DR:D06399]
マイトマイシンC [DR:D00208]
ドキソルビシン塩酸塩 [DR:D01275]
エピルビシン塩酸塩 [DR:D02214]
アクラルビシン塩酸塩 [DR:D01911]
ピラルビシン塩酸塩 [DR:D08386]
ビノレルビン酒石酸塩 [DR:D01935]
パクリタキセル [DR:D00491]
ドセタキセル水和物 [DR:D02165]
ドセタキセル [DR:D07866]
イリノテカン塩酸塩水和物 [DR:D01061]
ミトキサントロン塩酸塩 [DR:D02166]
パルボシクリブ [DR:D10372] (ホルモン受容体陽性, HER2陰性)
アベマシクリブ [DR:D10688] (ホルモン受容体陽性, HER2陰性)
ラパチニブトシル酸塩水和物 [DR:D04024] (HER2過剰発現)
カルボプラチン [DR:D01363]
トラスツズマブ [DR:D03257] (HER2過剰発現)
ベバシズマブ [DR:D06409]
ペルツズマブ [DR:D05446] (HER2陽性)
トラスツズマブエムタンシン [DR:D09980] (HER2陽性)
アテゾリズマブ [DR:D10773] (PD-L1陽性, ホルモン受容体陰性, HER2陰性)
トラスツズマブデルクステカン [DR:D11529] (HER2陽性)
オラパリブ [DR:D09730] (BRCA遺伝子変異陽性, HER2陰性)
エリブリンメシル酸塩 [DR:D08914]
タモキシフェンクエン酸塩 [DR:D00966]
トレミフェンクエン酸塩 [DR:D00967]
フルベストラント [DR:D01161]
アナストロゾール [DR:D00960]
レトロゾール [DR:D00964]
エキセメスタン [DR:D00963]
コメント  
ICD-O: 8500/3, Tumor type: Invasive ductal carcinoma, not otherwise specified
ICD-O: 8520/3, Tumor type: Invasive lobular carcinoma
リンク   
ICD-11: 2C61
ICD-10: C50
MeSH: D001943
文献    
PMID:10448115 (gene, tumor type)
  著者
Ingvarsson S.
  タイトル
Molecular genetics of breast cancer progression.
  雑誌
Semin Cancer Biol 9:277-88 (1999)
DOI:10.1006/scbi.1999.0124
文献    
  著者
Dai X, Xiang L, Li T, Bai Z
  タイトル
Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes.
  雑誌
J Cancer 7:1281-94 (2016)
DOI:10.7150/jca.13141
文献    
  タイトル
Comprehensive molecular portraits of human breast tumours.
  雑誌
Nature 490:61-70 (2012)
DOI:10.1038/nature11412
文献    
  著者
Zhang MH, Man HT, Zhao XD, Dong N, Ma SL
  タイトル
Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review).
  雑誌
Biomed Rep 2:41-52 (2014)
DOI:10.3892/br.2013.187
文献    
  著者
Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA
  タイトル
Triple-negative breast cancer: risk factors to potential targets.
  雑誌
Clin Cancer Res 14:8010-8 (2008)
DOI:10.1158/1078-0432.CCR-08-1208
文献    
  著者
King TD, Suto MJ, Li Y
  タイトル
The Wnt/beta-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer.
  雑誌
J Cell Biochem 113:13-8 (2012)
DOI:10.1002/jcb.23350
文献    
  著者
Jamdade VS, Sethi N, Mundhe NA, Kumar P, Lahkar M, Sinha N
  タイトル
Therapeutic targets of triple-negative breast cancer: a review.
  雑誌
Br J Pharmacol 172:4228-37 (2015)
DOI:10.1111/bph.13211
文献    
PMID:17464097 (carcinogen)
  著者
Ito K.
  タイトル
Hormone replacement therapy and cancers: the biological roles of estrogen and progestin in tumorigenesis are different between the endometrium and breast.
  雑誌
Tohoku J Exp Med 212:1-12 (2007)
DOI:10.1620/tjem.212.1
文献    
PMID:17135036 (carcinogen)
  著者
Schmidt JW, Wollner D, Curcio J, Riedlinger J, Kim LS.
  タイトル
Hormone replacement therapy in menopausal women: Past problems and future possibilities.
  雑誌
Gynecol Endocrinol 22:564-77 (2006)
DOI:10.1080/09513590600927017
文献    
PMID:15192054 (carcinogen)
  著者
.
  タイトル
Hormones and breast cancer.
  雑誌
Hum Reprod Update 10:281-93 (2004)
DOI:10.1093/humupd/dmh025
文献    
PMID:14534338 (carcinogen)
  著者
Petitti DB.
  タイトル
Clinical practice. Combination estrogen-progestin oral contraceptives.
  雑誌
N Engl J Med 349:1443-50 (2003)
DOI:10.1056/NEJMcp030751
文献    
PMID:16278609 (carcinogen)
  著者
Shah NR, Borenstein J, Dubois RW.
  タイトル
Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis.
  雑誌
Menopause 12:668-78 (2005)
DOI:10.1097/01.gme.0000184221.63459.e1
文献    
PMID:10564925 (carcinogen)
  著者
Nekolla EA, Kellerer AM, Kuse-Isingschulte M, Eder E, Spiess H.
  タイトル
Malignancies in patients treated with high doses of radium-224.
  雑誌
Radiat Res 152:S3-7 (1999)
DOI:10.2307/3580102
文献    
PMID:15070562 (carcinogen)
  著者
Berrington de Gonzalez A, Darby S.
  タイトル
Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries.
  雑誌
Lancet 363:345-51 (2004)
DOI:10.1016/S0140-6736(04)15433-0

» English version

DBGET integrated database retrieval system